COSMO Pharmaceuticals Stock

CHF61.10

1.93% today

SIX Swiss Exchange, Jul 17, 11:25 am CET

ISIN

NL0011832936

Symbol

COPN

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

COSMO Pharmaceuticals Stock price

CHF62.30

-28.40 31.31% 5Y

SIX Swiss Exchange, Closing price Wed, Jul 16 2025

+0.30 0.48%

ISIN

NL0011832936

Symbol

COPN

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

CHF1.0b

Enterprise Value

CHF912.8m

Net debt

positive

Cash

CHF133.2m

Shares outstanding

16.0m

Valuation (TTM | estimate)

P/E

8.3 | 11.1

P/S

4.2 | 5.1

EV/Sales

3.7 | 4.4

EV/FCF

6.2

P/B

2.3

Dividends

DPS

CHF1.95

Yield 1Y | 5Y

3.1% | 1.3%

Growth 1Y | 5Y

100.0% | -

Payout 1Y | 3Y

0.0% | 25.1%

Increased

1 Year

Financials (TTM | estimate)

Revenue

CHF248.6m | CHF203.2m

EBITDA

CHF150.2m | CHF82.5m

EBIT

CHF138.7m | CHF120.9m

Net Income

CHF124.2m | CHF89.9m

Free Cash Flow

CHF146.1m

Growth (TTM | estimate)

Revenue

187.5% | -18.1%

EBITDA

7,262.7% | -41.1%

EBIT

8,040.4% | -12.7%

Net Income

1,335.5% | -27.5%

Free Cash Flow

755.8%

Financial Health

Equity Ratio

77.1%

Return on Equity

26.7%

ROCE

24.9%

ROIC

28.2%

Debt/Equity

0.0

EPS

CHF7.5

FCF per Share

CHF9.1

Short interest

Employees

322

Rev per Employee

CHF770.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

COSMO Pharmaceuticals Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a COSMO Pharmaceuticals forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a COSMO Pharmaceuticals forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from COSMO Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	249 249	188% 188% 100%
- Direct Costs	42 42	15% 15% 17%
Gross Profit	206 206	314% 314% 83%
- Selling and Administrative Expenses	34 34	21% 21% 14%
- Research and Development Expense	37 37	46% 46% 15%
EBITDA	150 150	7,263% 7,263% 60%
- Depreciation and Amortization	11 11	202% 202% 5%
EBIT (Operating Income) EBIT	139 139	8,040% 8,040% 56%
Net Profit	124 124	1,336% 1,336% 50%

In millions CHF.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Head office	Netherlands
CEO	Giovanni Napoli
Employees	322
Founded	2016
Website	www.cosmopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now